Following locations in Singapore, Japan and South Korea, the new sales office in Shanghai is the fourth Vetter office in the Asia-Pacific region (APAC). The local presence is intended to address up-and-coming Chinese companies and support them in their access to the global market with a comprehensive service portfolio from Vetter. At the same time, the move emphasizes the relevance of the Chinese market for Vetter and solidifies the company's international focus.
"We are convinced that our continued investment in the Asia Pacific region will significantly contribute to our future global growth," said Vetter CEO Peter Sölkner. “With an increased share of Asian firms among the Top 50 Pharma companies worldwide over the last several years, our mission is to service the needs of our global customer base, of course including Asia, in the best-possible way.”
China, as the world's second largest drug market with constant growth rates, offers promising potential for injectable drugs. Oskar Gold, Senior Vice President Asia-Pacific/Emerging Global Markets explains, “Our presence in China demonstrates our dedication in one of the most important markets of the APAC region and will help to increase the awareness of Vetter’s services by presenting our expertise and market position onsite.”
The new office, located in the heart of Shanghai's Central Business District, will open on March 8, 2021, and will be headed by Jason Zhong, Business Development Manager China.